Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer

Lee, Kyung Hee; Hyun, Myung Soo; Kim, Hoon-Kyo; Jin, Hyung Min; Yang, Jung–Min; Song, Hong Suk; Rok, Young; Ryoo, Hun Mo; Chung, Joo Seop; Zang, Dae Young; Lim, Ho-Yeong; Jin, Jong Youl; Yim, Chang Yeol; Park, Hee Sook; Kim, Jun Suk; Sohn, Chang Hak; Lee, Soon Nam

doi:10.4143/crt.2009.41.1.12

Cited by 32 publications

(8 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is currently used in the treatment of gastric cancer [37]. A recent Phase III study indicated that heptaplatin/5-FU regimen is comparable to cisplatin/5-FU regimen, but has less severe hematological side effects [38]. No study of this regimen in cisplatin resistant cancers has been reported so far.…”

Section: Platinum Anticancer Drugs In Oncologymentioning

confidence: 99%

Nanocarriers for delivery of platinum anticancer drugs

Oberoi¹,

Nukolova²,

Kabanov³

et al. 2013

Advanced Drug Delivery Reviews

361

309

View full text Add to dashboard Cite

Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clinical use especially for management of tumors of the ovary, testes, and the head and neck. However, several dose limiting toxicities associated with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life. These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy. Nanocarrier-based delivery of platinum compounds is one such area of intense research effort beginning to provide encouraging preclinical and clinical results and may allow the development of the next generation of platinum chemotherapy. This review highlights current understanding on the pharmacology and limitations of platinum compounds in clinical use, and provides a comprehensive analysis of various platinum–polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.

show abstract

Section: Platinum Anticancer Drugs In Oncologymentioning

confidence: 99%

Nanocarriers for delivery of platinum anticancer drugs

Oberoi¹,

Nukolova²,

Kabanov³

et al. 2013

Advanced Drug Delivery Reviews

361

309

View full text Add to dashboard Cite

show abstract

“…It is more active than carboplatin and has similar efficacy to cisplatin. Lobaplatin is used in China for the treatment of chronic myelogenous leukemia (CML), inoperable metastatic breast cancer and SCLC and heptaplatin is approved in Korea for the treatment of gastric cancer [9,10].…”

Section: Introductionmentioning

confidence: 99%

What do we know about the reduction of Pt(IV) pro-drugs?

Wexselblatt

Gibson

2012

Journal of Inorganic Biochemistry

324

320

View full text Add to dashboard Cite

“…Molecular simulation is a well-developed methodology for identifying synergism in drug combinations (Chou 2006), and virtual clinical trials, which rely on pharmacodynamic and pharmacokinetic models to analyze different drug combinations, can also be used to suggest new treatments (Kleiman et al 2009). Animal studies and in vitro experimentation can be used to further evaluate novel chemotherapy regimens; results of these preclinical studies are often cited as motivations for phase II studies of combination chemotherapy regimens (Chao et al 2006, Iwase et al 2011, Lee et al 2009. A key limitation of current preclinical models is that most do not incorporate treatment outcomes from actual patients, whereas the new models we propose in this work leverage patient outcomes reported in previous clinical trials.…”

Section: Selection Of Previously Tested Chemotherapy Regimens For Furmentioning

confidence: 99%

An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer

et al. 2016

View full text Add to dashboard Cite

C ancer is a leading cause of death worldwide, and advanced cancer is often treated with combinations of multiple chemotherapy drugs. In this work, we develop models to predict the outcomes of clinical trials testing combination chemotherapy regimens before they are run and to select the combination chemotherapy regimens to be tested in new phase II and phase III clinical trials, with the primary objective of improving the quality of regimens tested in phase III trials compared to current practice. We built a database of 414 clinical trials for advanced gastric cancer and use it to build statistical models that attain an out-of-sample R 2 of 0.56 when predicting a trial's median overall survival (OS) and an out-of-sample area under the curve (AUC) of 0.83 when predicting if a trial has unacceptably high toxicity. We propose models that use machine learning and optimization to suggest regimens to be tested in phase II and phase III trials. Though it is inherently challenging to evaluate the performance of such models without actually running clinical trials, we use two techniques to obtain estimates for the quality of regimens selected by our models compared with those actually tested in current clinical practice. Both techniques indicate that the models might improve the efficacy of the regimens selected for testing in phase III clinical trials without changing toxicity outcomes. This evaluation of the proposed models suggests that they merit further testing in a clinical trial setting.

show abstract

Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer

Cited by 32 publications

References 66 publications

Nanocarriers for delivery of platinum anticancer drugs

Nanocarriers for delivery of platinum anticancer drugs

What do we know about the reduction of Pt(IV) pro-drugs?

An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer

Contact Info

Product

Resources

About